Pharmaceutical & FDA Compliant Marketing

What this service is

Pharmaceutical and healthcare marketing is a different discipline to consumer marketing, and treating it as consumer marketing with extra legal review is how campaigns end up rebuilt from scratch or, worse, receiving a letter from the regulator.

The constraints are structural rather than cosmetic. In the United States, promotional communications about prescription drugs are overseen by the FDA’s Office of Prescription Drug Promotion (OPDP), and they carry requirements that shape the creative before a single frame is shot: claims must be substantiated, benefit and risk must be presented with fair balance, and material facts about the product cannot be omitted.

WVE’s position is that these constraints are a creative brief rather than an obstacle. A fifteen-second video that has to carry fair balance is a genuinely harder problem than one that does not — but it is a solvable one, and solving it well is more valuable than avoiding the category.

WVE works with the pharmaceutical company Neurelis, which is why regulated marketing is a standing service line rather than an occasional exception.

Who it is for

• Pharmaceutical companies marketing prescription products to patients or healthcare professionals.
• Biotechnology companies approaching a launch and building awareness ahead of it.
• Healthcare and wellness brands whose claims fall under regulatory scrutiny.
• Medical device companies with comparable promotional constraints.
• Patient advocacy and disease-awareness programmes that need reach without making product claims.

It is particularly relevant to organisations that know their audience has moved to social platforms but do not believe compliant work can be done there. That belief is common and it is wrong — but it is understandable, because most agencies offering to prove otherwise do not understand the review process they are about to enter.

The regulatory landscape this work operates in

The following describes the publicly documented regulatory framework that governs pharmaceutical promotion in the United States. It is context for how campaigns are built, not a description of WVE’s legal advice — regulatory sign-off always rests with the client’s own medical, legal and regulatory function.

FDA oversight and fair balance

Prescription drug promotion in the US is regulated by the FDA, with OPDP responsible for reviewing promotional materials. The central requirement is fair balance: information about a product’s risks must be presented with comparable prominence and readability to information about its benefits.

In practice this rules out a great deal of standard social creative. A hook that leads with an unqualified benefit claim, or a format with no room for risk information, cannot be made compliant by adding a caption. It has to be designed differently from the start.

Indication, claims and off-label promotion

Promotion must stay within a product’s approved indication. Suggesting uses beyond what the label supports — off-label promotion — is one of the most serious compliance failures in the category, and it can happen accidentally through imprecise creative language or through where a piece of content is placed.

Substantiation

Claims must be supported by adequate evidence. This affects how campaigns are written: comparative or superiority language requires substantiation to match, and creative that depends on such language is a liability if the evidence does not exist.

HIPAA and audience targeting

HIPAA governs protected health information in the United States. Even where a marketing platform is not itself a covered entity, health-adjacent targeting raises real privacy exposure — building or using audience segments that effectively infer an individual’s health condition is a risk regardless of which regulation technically applies.

WVE’s approach is HIPAA-conscious targeting: reaching relevant audiences through context, content affinity and interest signals rather than through inferred diagnosis. It is both the defensible choice and, in most cases, the more effective one, because content-led targeting reaches people at the moment they are actually seeking information.

Adverse event reporting

Running social channels in this category creates a monitoring obligation. Users disclose side effects in comments and messages, and those disclosures may constitute reportable adverse events. Any compliant social programme needs an agreed process for identifying and escalating them to the client’s pharmacovigilance function.

How it is delivered

Compliance-first creative development

Concepts are developed against regulatory constraints from the first round rather than being tested for compliance at the end. This is the single largest saving available in the category: creative that fails review late costs a full production cycle, and often the launch window with it.

Built for medical, legal and regulatory review

Work is prepared to move through MLR review efficiently — claims mapped to their substantiation, risk information integrated into the format rather than appended to it, and reviewers given what they need to make a decision quickly.

Patient education

Disease awareness and patient education content operates under different constraints to branded promotion, and can often reach audiences that branded content cannot. Done properly it is genuinely useful — patients researching a condition are underserved by the material currently available to them, and there is a real opportunity in being the clearest, most trustworthy answer.

This is also where WVE’s wider capability transfers most directly: patients search, and increasingly they ask AI answer engines. Being accurately represented in those answers is a distribution channel most pharmaceutical brands have not addressed.

Healthcare professional audiences

HCP-directed promotion has different requirements and different channels to patient-directed work, and the two need to be planned separately even when they support the same product.

Culture-fluent creative within the constraints

The reason to bring a culture marketing agency into a regulated category is that compliant does not have to mean forgettable. WVE brings the same understanding of platform formats, trends and creator distribution that it applies for consumer brands — then works within the constraints instead of pretending they are not there.

Health decisions are made by people who spend their attention in exactly the same places as everyone else. The brands that reach them are the ones that respect both the regulation and the platform.

Results

WVE works with the pharmaceutical company Neurelis.

The broader capability behind this service has delivered 25+ billion accounts reached, 850+ billion impressions and an average paid-media return on ad spend of 18.6× across all categories.

How this connects to the rest of the work

Regulated campaigns use the same underlying capability as the rest of WVE’s work — social distribution, paid media, creative production and measurement — with the constraints of the category applied from the first creative round rather than the last.

Frequently asked questions

Does WVE work with pharmaceutical companies?

Yes. Pharmaceutical and FDA-compliant marketing is a standing WVE service line, and WVE works with the pharmaceutical company Neurelis. The work covers compliant campaign creative, HIPAA-conscious audience targeting, and patient education.

What does FDA-compliant marketing mean?

In the United States, promotional communications about prescription drugs are overseen by the FDA’s Office of Prescription Drug Promotion. Compliant marketing means claims are substantiated, benefit and risk information are presented with fair balance and comparable prominence, promotion stays within the product’s approved indication, and material facts are not omitted. In practice it means creative has to be designed around those requirements from the start rather than reviewed for them at the end.

Can pharmaceutical brands run social media campaigns compliantly?

Yes, but the creative has to be built for it. Short-form formats that lead with an unqualified benefit claim, or that leave no room for risk information, cannot be made compliant with a caption — fair balance has to be designed into the format. Social channels in this category also require a process for identifying and escalating adverse events disclosed by users.

What is HIPAA-conscious targeting?

It means reaching relevant audiences through context, content affinity and interest signals rather than through segments that infer an individual’s health condition. Health-adjacent targeting carries real privacy exposure even where a platform is not itself a HIPAA covered entity, and context-led targeting is both the more defensible approach and frequently the more effective one, because it reaches people at the moment they are seeking information.

How does WVE handle medical, legal and regulatory review?

Creative is developed against regulatory constraints from the first round, with claims mapped to their substantiation and risk information integrated into the format rather than appended to it, so that work moves through MLR review efficiently. Regulatory sign-off always rests with the client’s own medical, legal and regulatory function.

Does WVE market to healthcare professionals as well as patients?

HCP-directed and patient-directed promotion have different requirements and different channels, and are planned separately even when supporting the same product.

What is the difference between branded promotion and disease awareness?

Branded promotion names a product and therefore carries the full set of promotional requirements including fair balance. Disease awareness and patient education content does not make product claims, operates under different constraints, and can often reach audiences branded content cannot. Many pharmaceutical programmes use both, planned together.

Related services

• Data Tracking & Optimization — We track your performance in real time, predict what's about to trend, monitor how users behave on your site, capture new audiences, and optimize ads with data-driven insights.
• Paid & Organic Media Engine — We drive growth and scale brands with paid ads on across all major platforms, paired with organic strategies, influencer partnerships, precise audience targeting, and traditional media buying.
• Design & Creative Services — From brand identities and logos to websites, mobile apps, packaging, and digital products, our award-winning designers build work that commands attention and defines categories.

Or see all eight services and how they fit together.